Sodium Valproate Prophylaxis in Childhood Migraine

Serdaroğlu, Gül; Erhan, Elvan; Tekgül, Hasan; Oksel, Figen; Erermiş, Serpil; Uyar, Meltem; Tütüncüoğlu, Sarenur

doi:10.1046/j.1526-4610.2002.02186.x

Cited by 90 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Side effects included dizziness, drowsiness, and increased appetite, but no serious side effects were noted in this small study. 38 Caution must be exercised with the use of divalproex sodium in women of childbearing potential.…”

Section: Description Of Processmentioning

confidence: 99%

Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents [RETIRED]

et al. 2004

View full text Add to dashboard Cite

Abstract-Objective:To review evidence on the pharmacologic treatment of the child with migraine headache. Methods: The authors reviewed, abstracted, and classified relevant literature. Recommendations were based on a four-tiered scheme of evidence classification. Treatment options were separated into medications for acute headache and preventive medications. Results: The authors identified and reviewed 166 articles. For acute treatment, five agents were reviewed. Sumatriptan nasal spray and ibuprofen are effective and are well tolerated vs placebo. Acetaminophen is probably effective and is well tolerated vs placebo. Rizatriptan and zolmitriptan were safe and well tolerated but were not superior to placebo. For preventive therapy, 12 agents were evaluated. Flunarizine is probably effective. The data concerning cyproheptadine, amitriptyline, divalproex sodium, topiramate, and levetiracetam were insufficient. Conflicting data were found concerning propranolol and trazodone. Pizotifen, nimodipine, and clonidine did not show efficacy. Conclusions: For children (Ͼage 6 years), ibuprofen is effective and acetaminophen is probably effective and either can be considered for the acute treatment of migraine. For adolescents (Ͼ12 years of age), sumatriptan nasal spray is effective and should be considered for the acute treatment of migraine. For preventive therapy, flunarizine is probably effective and can be considered, but is not available in the United States. There are conflicting or insufficient data to make any other recommendations for the preventive therapy of migraine in children and adolescents. For a clinical problem so prevalent in children and adolescents, there is a disappointing lack of evidence from controlled, randomized, and masked trials.

show abstract

Section: Description Of Processmentioning

confidence: 99%

Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents [RETIRED]

et al. 2004

View full text Add to dashboard Cite

show abstract

“…76% of patients in this open label trial had a greater than 50% reduction in headache frequency. Another open label trial of either 500 mg or 1000 mg of sodium divalproex showed a reduction in headache frequency from 6 per month to 0.7 per month [47]. Because of divalproex's potential effects on bone marrow, liver, and pancreas, routine serum evaluation is needed.…”

Section: Journal Of Headache and Pain Management Issn 2472-1913mentioning

confidence: 99%

Recent developments in the treatment of migraine in children and adolescents

Freitag

Schloemer²,

Shumate

2016

J Headache Pain Manag

View full text Add to dashboard Cite

“…Ограничением к использованию может послужить разви-тие НЛР в виде головокружения, сонливости, повышения массы тела, выпадения волос, гепатотоксичности [17,18].…”

Section: профилактическая терапия мигрениunclassified

Migraine and Tension-Type Headache in Children: The Approach to Effective Treatment. Part 2

Sergeev¹

2012

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Доказательная база по эффективности и безопас-ности фармакотерапии головных болей (ГБ) у детей огра-ничена. Детским неврологам приходится использовать неодобренные для применения в педиатрической прак-тике лекарственные средства, индивидуально взвеши-вая возможную пользу и риск развития нежелательных лекарственных реакций. Отсутствие в России четких рекомендаций по симптоматической и профилактиче-ской терапии первичных ГБ в детском возрасте зача-стую приводит к назначению неэффективной (Но-шпа, ноотропы, «сосудистые» препараты, гомеопатические средства) и небезопасной (купирование эпизодов ГБ комбинированными анальгетиками, содержащими метамизол натрия, кодеин или фенобарбитал) терапии. Нередкое следствие таких назначений -ухудшение течения мигрени и головной боли напряжения (ГБН) с формированием хронической ежедневной головной боли, лекарственно-индуцированной головной боли и развитием серьезных нежелательных лекарственных реакций (НЛР).Фармакотерапию мигрени и ГБН подразделяют на симптоматическую (эпизодический прием препарата с целью купирования приступа боли) и профилактическую (регулярная, длительная терапия, направленная на сни-жение частоты и интенсивности болевых приступов). ФАРМАКОТЕРАПИЯ МИГРЕНИСимптоматическая терапия мигрени Целью симптоматической терапии служит быстрое и эффективное купирование приступа ГБ с полной нор-мализацией повседневной активности ребенка и отсут-ствием рецидива болевого синдрома.Основными принципами симптоматического лече-ния приступа мигрени у детей являются следующие:

show abstract

Sodium Valproate Prophylaxis in Childhood Migraine

Abstract: Sodium valproate appears to be effective and safe in selected patients with childhood migraine.

Cited by 90 publications

References 16 publications

Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents [RETIRED]

Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents [RETIRED]

Recent developments in the treatment of migraine in children and adolescents

Migraine and Tension-Type Headache in Children: The Approach to Effective Treatment. Part 2

Contact Info

Product

Resources

About